Pipeline
Our robust pipeline includes several promising candidates at various stages of development, from discovery to clinical trials.
AbBC’s therapeutic pipeline is built on a proprietary Granzyme B–Fc fusion platform that delivers a consistent and well-defined mechanism of action across all targets. While each candidate is directed against a distinct disease-associated surface antigen, all programs leverage the same Granzyme B–mediated intracellular apoptotic pathway. This platform architecture enables rapid generation of new candidates with shared pharmacologic principles, reducing development risk while efficiently expanding portfolio breadth across multiple oncology indications.
